Analyst firms · Oppenheimer · SRPT

Oppenheimer SRPT price target and rating history

Sarepta Therapeutics Inc. (SRPT) · Health Care

Oppenheimer rates Sarepta Therapeutics Inc. (SRPT) Outperform with a $37 price target, as of its latest action on Jul 29, 2025. It has published 4 rating actions on SRPT since December 2021, including 3 upgrades and 1 downgrade. Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50.

Current rating
Outperform
Price target
$37
Median target, all firms
$23.50
Actions on SRPT
4

Oppenheimer price target on SRPT

$180$109$3720222023202420252026
Oppenheimer price target on SRPT, each point a stated target, December 2021 to July 2025.

Every Oppenheimer rating on SRPT

How other firms rate SRPT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Deutsche BankHold$18Nov 10, 2026
Wolfe ResearchOutperform$27Jul 9, 2026
BarclaysEqual Weight$20Jan 28, 2026
WedbushOutperform$32Dec 9, 2025

Questions about Oppenheimer and SRPT

What is Oppenheimer's price target for SRPT?
Oppenheimer's latest stated price target for Sarepta Therapeutics Inc. (SRPT) is $37, from its action on Jul 29, 2025.
What is Oppenheimer's rating on SRPT?
Oppenheimer rates SRPT Outperform, a bullish rating, as of Jul 29, 2025.
When did Oppenheimer last change its view on SRPT?
On Jul 29, 2025, Oppenheimer upgrades to Outperform from Perform, price target $37.
How does Oppenheimer's SRPT target compare with other analysts?
Across 4 firms with a SRPT price target in the last 12 months, the median target is $23.50.

More SRPT rating histories

All Oppenheimer ratingsSRPT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.